You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 132 No. 3, March 1996 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  STUDIES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (27)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Long-term Follow-up of Non-HIV Kaposi's Sarcoma Treated With Low-Dose Recombinant Interferon Alfa-2b

Claudia S. Costa da Cunha, MD; Céleste Lebbé, MD, PhD; Michel Rybojad, MD; Félix Agbalika, MD; Françoise Ferchal, MD; Claire Rabian, MD; Marie D. Vignon-Pennamen, MD; Fabien Calvo, MD, PhD; Patrice Morel, MD

Arch Dermatol. 1996;132(3):285-290.


Abstract



Background and Design
We reviewed the follow-up of 16 patients with Kaposi's sarcoma not related to human immunodeficiency virus (13 with classic Kaposi's sarcoma and three with endemic Kaposi's sarcoma; median age, 58 years) treated by low-dose recombinant interferon alfa-2b (5 million U three times weekly for at least 6 months).

Results
One patient had a complete response, nine had a major response, three had stable disease, and one had a minor response. Visceral disease stabilized and symptoms improved in three patients. Limited relapse was noted in four patients after withdrawal of interferon.

Conclusion
Our results confirm the efficacy and safety of low-dose recombinant interferon alfa-2b in the longterm treatment of both cutaneous and visceral lesions of Kaposi's sarcoma not related to human immunodeficiency virus.

(Arch Dermatol. 1996;132:285-290)



Author Affiliations



From the Departments of Dermatology (Drs Costa da Cunha, Lebbé, Rybojad, and Morel), Virology (Drs Agbalika and Ferchal), Immunology (Dr Rabian), and Histology (Dr Vignon-Pennamen) and Laboratory of Pharmacology (Dr Calvo), Hôpital Saint Louis, Paris, France.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia-Associated Aggressive Classic Kaposi's Sarcoma during Interferon-{alpha} Therapy: A Case Report
Monini et al.
Clinical Infectious Diseases 2001;33:1782-1785.
ABSTRACT | FULL TEXT  

Classic Kaposi's Sarcoma Associated with Human Herpesvirus 8 Infection in a 13-Year-Old Male: A Case Report
Landau et al.
Clin. Cancer Res. 2001;7:2263-2268.
ABSTRACT | FULL TEXT  

Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells
Monini et al.
J. Virol. 1999;73:4029-4041.
ABSTRACT | FULL TEXT  

Recombinant Interleukin 2 Monotherapy for Classic Kaposi Sarcoma
Shibagaki et al.
Arch Dermatol 1998;134:1193-1196.
FULL TEXT  

Kaposi Sarcoma Unrelated to Human Immunodeficiency Virus Infection: Long-term Results of Radiotherapy
Gonzalez-Acosta et al.
Arch Dermatol 1997;133:107-108.
ABSTRACT  

Treatment of Kaposi's Sarcoma
Tur et al.
Arch Dermatol 1996;132:327-331.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.